Adjusted probability of survival in adult AML patients who underwent HLA-identical sibling (MRD) HCT or 8/8 or 7/8 matched unrelated donor (MUD) HCT at 6 mo, 1 y, 2 y, and 3 y
| . | MRD, % (95% CI) . | 8/8 MUD, % (95% CI) . | 7/8 MUD, % (95% CI) . | 8/8 MUD vs MRD, P* . | 7/8 MUD vs MRD, P* . | 7/8 MUD vs 8/8 MUD, P* . |
|---|---|---|---|---|---|---|
| @ 6 mo | 71 (67-75) | 67 (65-70) | 60 (55-64) | .09 | < .001 | .005 |
| @ 1 y | 53 (49-57) | 52 (50-55) | 47 (42-51) | .73 | .04 | .04 |
| @ 2 y | 42 (38-46) | 42 (39-44) | 40 (35-44) | .90 | .51 | .52 |
| @ 3 y | 37 (33-41) | 37 (34-40) | 36 (31-41) | .97 | .76 | .71 |
| . | MRD, % (95% CI) . | 8/8 MUD, % (95% CI) . | 7/8 MUD, % (95% CI) . | 8/8 MUD vs MRD, P* . | 7/8 MUD vs MRD, P* . | 7/8 MUD vs 8/8 MUD, P* . |
|---|---|---|---|---|---|---|
| @ 6 mo | 71 (67-75) | 67 (65-70) | 60 (55-64) | .09 | < .001 | .005 |
| @ 1 y | 53 (49-57) | 52 (50-55) | 47 (42-51) | .73 | .04 | .04 |
| @ 2 y | 42 (38-46) | 42 (39-44) | 40 (35-44) | .90 | .51 | .52 |
| @ 3 y | 37 (33-41) | 37 (34-40) | 36 (31-41) | .97 | .76 | .71 |
Point-wise pairwise comparison.